264 related articles for article (PubMed ID: 21669426)
1. Combined contraceptive ring versus combined oral contraceptive (30-μg ethinylestradiol and 3-mg drospirenone).
Mohamed AM; El-Sherbiny WS; Mostafa WA
Int J Gynaecol Obstet; 2011 Aug; 114(2):145-8. PubMed ID: 21669426
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial.
Fan GS; Ren M; Di W; Su P; Chang Q; Wu S; Qin Y; Korver T; Marintcheva-Petrova M; Yacik C; McCrary Sisk C; Wang G
Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):303-9. PubMed ID: 27339759
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
[TBL] [Abstract][Full Text] [Related]
4. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
Milsom I; Lete I; Bjertnaes A; Rokstad K; Lindh I; Gruber CJ; Birkhäuser MH; Aubeny E; Knudsen T; Bastianelli C
Hum Reprod; 2006 Sep; 21(9):2304-11. PubMed ID: 16763008
[TBL] [Abstract][Full Text] [Related]
5. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing.
Bruni V; Pontello V; Luisi S; Petraglia F
Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):65-71. PubMed ID: 18358586
[TBL] [Abstract][Full Text] [Related]
6. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.
Anttila L; Neunteufel W; Petraglia F; Marr J; Kunz M
Clin Drug Investig; 2011; 31(8):519-525. PubMed ID: 21721590
[TBL] [Abstract][Full Text] [Related]
7. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
[TBL] [Abstract][Full Text] [Related]
8. [Combined hormonal contraception in cycles artificially extended].
Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial.
Oddsson K; Leifels-Fischer B; de Melo NR; Wiel-Masson D; Benedetto C; Verhoeven CH; Dieben TO
Contraception; 2005 Mar; 71(3):176-82. PubMed ID: 15722066
[TBL] [Abstract][Full Text] [Related]
10. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
Gaspard U; Scheen A; Endrikat J; Buicu C; Lefebvre P; Gerlinger C; Heithecker R
Contraception; 2003 Jun; 67(6):423-9. PubMed ID: 12814810
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of bleeding patterns in women using a combined contraceptive vaginal ring or a low-dose combined oral contraceptive on a menstrually signaled regimen.
Weisberg E; Merki-Feld GS; McGeechan K; Fraser IS
Contraception; 2015 Feb; 91(2):121-6. PubMed ID: 25459098
[TBL] [Abstract][Full Text] [Related]
12. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
Tuppurainen M; Klimscheffskij R; Venhola M; Dieben TO
Contraception; 2004 May; 69(5):389-94. PubMed ID: 15105061
[TBL] [Abstract][Full Text] [Related]
13. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
[TBL] [Abstract][Full Text] [Related]
15. An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods (UChoose).
Gill K; Happel AU; Pidwell T; Mendelsohn A; Duyver M; Johnson L; Meyer L; Slack C; Strode A; Mendel E; Fynn L; Wallace M; Spiegel H; Jaspan H; Passmore JA; Hosek S; Smit D; Rinehart A; Bekker LG
J Int AIDS Soc; 2020 Oct; 23(10):e25626. PubMed ID: 33034421
[TBL] [Abstract][Full Text] [Related]
16. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
Vree ML; Schmidt J
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
[TBL] [Abstract][Full Text] [Related]
17. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception.
Gallo MF; Nanda K; Grimes DA; Lopez LM; Schulz KF
Cochrane Database Syst Rev; 2011 Jan; (1):CD003989. PubMed ID: 21249657
[TBL] [Abstract][Full Text] [Related]
18. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
19. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Gerlinger C; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial].
Fan GS; Bian ML; Cheng LN; Cao XM; Huang ZR; Han ZY; Jing XP; Li J; Wu SY; Xiong CL; Xiong ZA; Yue TF
Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):38-44. PubMed ID: 19563061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
